An observational study in Arterial Hypertension, sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation. Recruiting at 17 sites in Russia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Hypertension with a site in Russia — 2 open to participants now, 4 under way, none of them phase 3. Hypertension · Russia.
Among the 10 studies in Hypertension with a site in Russia, this one is the only one that started in 2018, is one of 5 observational ones, and was the 1st registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →2 of the 10 studies in Hypertension with a site in Russia are open now. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,400 is above the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 207 across the 5 interventional studies, 550 across the 5 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 8 most frequent:
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation is the lead sponsor of 20 studies on the registry; 11 are open to participants now.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypertension with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04160533National Medical Research Center for Cardiology, Ministry of Health of Russian FederationRegistry of Arterial Hypertension | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Hypertension with a site in Russia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The problem of the quality of primary health care medical system for patients with arterial hypertension is acute for the investigator's country, as these diseases are the most common and cause the high mortality of the population.
The concept of "quality of primary health care medical system" includes its timeliness, accessibility and provision of medical care to the patient at the modern level, which is determined by the degree of performance by doctors of medical and diagnostic measures corresponding current clinical recommendations.
The system of cardiovascular desease registries, established in the Federal State Clinical Hospital of the Russian Federation Ministry of Public Health with the automated analysis of data on examination and treatment, in comparison with clinical Recommendations. It makes possibility to identify shortcomings and develop approaches to improving the provision of medical care to patients in real clinical practice.
Comparative analysis of the quality of examination and treatment in different samples of patients with cardiovascular desease, observed in 2018-2020, compared with results of previous years will identify ptrends in the provision of medical care to patients with cardiovascular desease.
The study will be conducted using the arterial hypertension registry method, which is a computer program with remote access that allows online collection medical data from medical primary care system. To minimize operator errors, doctors was trained before the work with the arterial hypertension registry. User's guide was developed and the rights of users was determined. Data of examination and treatment of patients from 18 years and older with an established diagnosis of hypertension will be added from outpatient cards into the registry of the arterial hypertension. The information is received by the Institution in an impersonal form through a certified dedicated security channel. Patients sign an informed consent for entering their medical data into the registry of arterial hypertension
outpatient patients from 18 to 99 years old with a diagnosis of hypertension
Inclusion Criteria: The diagnosis of arterial hypertension -
Exclusion Criteria: No diagnosis of arterial hypertension
-
Number of patients with blood pressure <140/90 mm Hg
The level of systolic and diastolic blood pressure measured according to the rules described in the clinical guidelines for the treatment and diagnosis of arterial hypertension of the European Society of Cardiology during the visit (mmHg) is entered into the database by doctors.
Time frame: 2018 - 2021 years
Number of patients with a history of myocardial infarction, chronic renal desease, chronic heart failure, atrial fibrillation.
Diagnosis data is entered by doctors as a "yes" or "no" category.
Time frame: 2018-2021
Antihypertensive medications
Antihypertensive drugs the patient takes are entered into the database. Drugs are analyzed by groups and daily dosages
Time frame: 2018-2021
Started Jun 2018 (actual). Primary completion is estimated for Dec 2026, 102 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation